国产精品免费一级在线观看_羞羞视频下载安装_女人午夜啪啪性刺激免费看_人人插人人费

產品資料

TAK-875(Fasiglifam),GPR40Agonist

如果您對該產品感興趣的話,可以
產品名稱: TAK-875(Fasiglifam),GPR40Agonist
產品型號: M60220-2s
產品展商: 其它品牌
產品文檔: 無相關文檔

簡單介紹

TAK-875(Fasiglifam),GPR40Agonist


TAK-875(Fasiglifam),GPR40Agonist  的詳細介紹
Product Information
Molecular Weight: 533.63
Formula: C29H32O7S.1/2H2O
Purity: ≥98%
CAS#: 1374598-80-7
Solubility: DMSO up to 100 mM
Chemical Name: (S)-2-(6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

TAK-875 (Fasiglifam) is the potent, selective and orally bioavailable partial GPR40 agonist with an EC50 ~14 nM. ?It has binding affinity to the human GPR40 receptor with Ki of 38 nM and the rat GPR40 receptor with Ki of 140 nM. TAK-875 has no agonist potency to other members of the FFA receptor family with EC50 >10 μM. The 2.3 ? resolution co-complex structure of hGPR40-TAK-875 reveals a unique binding mode of TAK-875 and suggests that entry to the non-canonical binding pocket most probably occurs via the lipid bilayer. Consistent with the activation of the Gqα-mediated signaling pathway, TAK-875 augments glucose-dependent insulin secretion in pancreatic β cells. Prolonged stimulation of GPR40/FFA1 by TAK-875 does not cause pancreatic β Cell dysfunction or induction of apoptosis. Termination phase III development of TAK-875 (Fasiglifam) for the potential treatment of type-2 diabetes mellitus was announced in 2013 due to concerns about liver safety.


How to Use:

  • In vitro:? TAK-875 was used at 1 μM final concentration in various in vitro assays.
  • In vivo: TAK-875 was dosed to female Wistar fatty rats subjected to oral glucose tolerance test via oral gavage at 3 mg/kg one hour before an oral glucose challenge. Formulation is 0.5% CMC/0.25% Tween 80 in water. In type 2 diabetic N-STZ-1.5 rats, administration of TAK-875 (1-10 mg/kg PO) shows a clear improvement in glucose tolerance and augments insulin secretion. TAK-875 (10 mg/kg, PO) significantly augments plasma insulin levels and reduces fasting hyperglycemia in male Zucker diabetic fatty rats.?


Reference:?

  1. 1.????? Negoro N, et al. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist. (2010) ACS Med Chem Lett. 1(6):290-4.
  2. 2.????? Tsujihata Y, et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. (2011) J Pharmacol Exp Ther. 339(1):228-37.
  3. 3.????? Srivastava A, et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. (2014) Nature. 513(7516):124-7.?

? ??
? ??


Products are for research use only. Not for human use.

?

產品留言
標題
聯系人
聯系電話
內容
驗證碼
點擊換一張
注:1.可以使用快捷鍵Alt+S或Ctrl+Enter發送信息!
2.如有必要,請您留下您的詳細聯系方式!

滬公網安備 31011202007337號